Compare COE & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | CSBR |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 81.0M |
| IPO Year | 2015 | 2015 |
| Metric | COE | CSBR |
|---|---|---|
| Price | $15.80 | $6.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.5K | 5.7K |
| Earning Date | 06-08-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.66 | $5.50 |
| 52 Week High | $56.13 | $8.74 |
| Indicator | COE | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 53.25 |
| Support Level | $14.99 | $6.11 |
| Resistance Level | $17.91 | $6.29 |
| Average True Range (ATR) | 1.15 | 0.28 |
| MACD | 0.31 | 0.02 |
| Stochastic Oscillator | 3.52 | 95.08 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.